Scholar4AI Updated 2026-10-31 19:11 UTC+09:00

Eli Lilly (United States)

Papers in the tracked journals with an author at Eli Lilly (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

Share: X LinkedIn Bluesky Threads Facebook Reddit Hacker News Hatena LINE Email
Copy:

← Corporate research

Key findings#

  • From 2017 to 2026 (so far), authors at Eli Lilly (United States) took part in 24 papers in the tracked journals, most of them in statistics (11), health economics and policy (11) and marketing (2).
  • 1 of them were published in 2025, against 0 in 2017.
  • Since 2023, the institutions with the most of these papers were Bristol-Myers Squibb (United Kingdom) (1), Bristol-Myers Squibb (United States) (1) and Florida State University (1).
  • The journals publishing most of them were Lifetime Data Analysis (3), Statistics & Probability Letters (1) and Journal of Statistical Planning and Inference (1).
  • The most-cited of them is “Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines” (The European Journal of Health Economics, 2020), with 310 citations.

Papers per year#

2017: 0 papers2018: 4 papers2019: 4 papers2020: 4 papers2021: 3 papers2022: 2 papers2023: 0 papers2024: 3 papers2025: 1 paper2026 (so far): 3 papers
20172026 (so far)
Papers per publication year and category
Category2017201820192020202120222023202420252026 (so far)
Statistics0200300312
Health Economics and Policy0233020001
Marketing0011000000
All categories0444320313

Where the papers come from#

Institutions with the most papers, since 2023
#InstitutionPapers
1Bristol-Myers Squibb (United Kingdom)1
2Bristol-Myers Squibb (United States)1
3Florida State University1
4Hospital Universitario 12 De Octubre1
5Indiana University Indianapolis1
6Indiana University School of Medicine1
7Information Management Services1
8London School of Hygiene & Tropical Medicine1
9National Cancer Institute1
Countries with the most papers, since 2023
#CountryPapers
1United States7
2United Kingdom3
3Australia1
4Spain1
5Netherlands1
Keywords with the most papers, since 2023
#KeywordPapers
1consistency2
2B-splines1
3Bayesian estimation1
4Bayesian linear regression1
5Gibbs sampling1
6Harris recurrence1
7alcohol consumption1
8asymptotic normality1
9behavioral risk factors1
10breast cancer clinical trials1

Most-cited papers#

Most-cited papers since 2017
#CitationsPer monthTitleJournalPublishedAuthors
13104.0Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelinesThe European Journal of Health Economics2020-06-08Matthew Kennedy-Martin, Bernhard Slaap, Michael J. Herdman et al.
2580.7Beauty in the eyes of its beholders: Effects of design novelty on consumer preferenceJournal of Retailing and Consumer Services2019-10-18Fu Liu, Z. A. Zhu, Haipeng Allan Chen et al.
3300.4Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class ApproachesPharmacoEconomics2020-03-04Marco Boeri, Daniel Saure, Alexander Schacht et al.
4240.3Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic ArthritisPharmacoEconomics - Open2019-06-08Natalie N. Boytsov, Xiang Zhang, Kristin A. Evans et al.
5180.2Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and ItalyThe European Journal of Health Economics2020-10-06Johannes Pöhlmann, Kirsi Norrbacka, K. Boye et al.
6170.2The Upside of Down: Presenting a Price in a Low or High Location Influences How Consumers Evaluate ItJournal of Retailing2020-03-30Michael J. Barone, Keith S. Coulter, Xingbo Li
7130.1A joint design for functional data with application to scheduling ultrasound scansComputational Statistics & Data Analysis2018-01-31So Young Park, Luo Xiao, Jayson D. Wilbur et al.
8100.1A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USAPharmacoEconomics2019-08-27Elizabeth Wehler, Natalie N. Boytsov, Claudia Nicolay et al.
980.1Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness EvaluationApplied Health Economics and Health Policy2018-03-10William J. Valentine, Kate Van Brunt, Kristina Secnik Boye et al.
1070.1Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims dataHealth Economics Review2018-08-27Johannes Clouth, Astra M. Liepa, Guido Moeser et al.
Cite this page

Scholar4AI. (2026). Eli Lilly (United States). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/eli-lilly-united-states

@misc{scholar4ai-companies-eli-lilly-united-states,
  author = {{Scholar4AI}},
  title = {Eli Lilly (United States)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/eli-lilly-united-states}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).